Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 known ✓ | Q99720 | 2/20 | 0.42 |
| ▸ | HTR1B known ✓ | P28222 | 1/20 | 0.36 |
| ▸ | SLC6A4 known ✓ | P31645 | 1/20 | 0.32 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.62 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.43 |
| ▸ | PAOX | Q6QHF9 | 1/20 | 0.42 |
| ▸ | CARM1 | Q86X55 | 2/20 | 0.39 |
| ▸ | PRMT6 | Q96LA8 | 2/20 | 0.39 |
| ▸ | PRMT8 | Q9NR22 | 2/20 | 0.39 |
| ▸ | PRMT3 | O60678 | 1/20 | 0.39 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | HTR2A | P28223 | 1/20 | 0.36 |
| ▸ | HRH1 | P35367 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | KDM4A | O75164 | 1/20 | 0.33 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL331659 | 0.95 | — | — | |
| SCHEMBL5909406 | 0.91 | EPHX1 (0.73) | EPHX1L3MBTL1SIGMAR1PAOXCARM1 | |
| SCHEMBL7519363 | 0.91 | EPHX1 (0.73) | EPHX1L3MBTL1SIGMAR1PAOXCARM1 | |
| SCHEMBL331550 | 0.91 | EPHX1 (0.73) | EPHX1L3MBTL1SIGMAR1PAOXCARM1 | |
| SCHEMBL7518935 | 0.91 | EPHX1 (0.73) | EPHX1L3MBTL1SIGMAR1PAOXCARM1 | |
| SCHEMBL7511253 | 0.91 | EPHX1 (0.73) | EPHX1L3MBTL1SIGMAR1PAOXCARM1 | |
| SCHEMBL6838885 | 0.91 | EPHX1 (0.73) | EPHX1L3MBTL1SIGMAR1PAOXCARM1 | |
| SCHEMBL7519351 | 0.91 | EPHX1 (0.73) | EPHX1L3MBTL1SIGMAR1PAOXCARM1 | |
| SCHEMBL8821784 | 0.91 | EPHX1 (0.62) | EPHX1L3MBTL1SIGMAR1PAOXCARM1 | |
| SCHEMBL7513715 | 0.91 | EPHX1 (0.73) | EPHX1L3MBTL1SIGMAR1PAOXCARM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6576791-B1 | Local anesthetic compounds and uses | THERAVANCE, INC. | 2003-06-10 | — | — | US | disclosed |
| US-20030044845-A1 | Novel therapeutic agents for membrane transporters | THERAVANCE BIOPHARMA R&D IP, LLC | 2003-03-06 | — | — | US | disclosed |
| US-6495681-B1 | PRODUCING LOCAL ANESTHESIA OF LONG-DURATION. THE COMPOUNDS OF THIS INVENTION ARE MULTIBINDING COMPOUNDS THAT COMPRISE FROM 2 TO 10 LIGANDS COVALENTLY ATTACHED TO A LINKER OR LINKERS, EACH LIGAND BEING CAPABLE OF BINDING TO A LIGAND BINDING SITE | THERAVANCE INC. | 2002-12-17 | — | — | US | disclosed |
| US-6462034-B1 | MULTIBINDING COMPOUNDS CONTAINING A SYMETRICAL DIAMINOTETRA-ETHERDODECANE RING WITH TWO SECONDARY AMIDE AND ADDITIONAL SUBSTITUENTS; VOLTAGE GATED SODIUM CHANNEL MODULATORS; LONG DURATION | THERAVANCE, INC. | 2002-10-08 | — | — | US | disclosed |
| US-6436919-B1 | LOCAL ANESTHETICS THAT HAVE LONGER DURATION OF ACTION WHILE REDUCING UNDESIRED SIDE EFFECTS | THERAVANCE INC. | 2002-08-20 | — | — | US | disclosed |
| US-6337423-B1 | BIND TO VOLTAGE-GATED SODIUM ION CHANNELS TO MODULATE ACTIVITY | ADVANCED MEDICINE, INC. | 2002-01-08 | — | — | US | disclosed |
| WO-1999064045-A9 | NOVEL THERAPEUTIC AGENTS FOR MEMBRANE TRANSPORTERS | ADVANCED MEDICINE INC (US) | 2001-07-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030044845-A1 | Novel therapeutic agents for membrane transporters | SLC47A2, SLC8B1, SLC47A1 | SIGMAR1 1130/4885HTR1B 1883/4885SLC6A4 86/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.